Skip to content
ABCL·Nasdaq·US

AbCellera

AbCellera is a biotechnology company that discovers and develops antibody therapeutics using a proprietary platform and partner collaborations. It generates revenue primarily from research fees, licensing income, milestone payments, and royalties tied to antibody discovery programs.

Recent Activity

Updated Sep 24, 2026
–AbCellera announced the presentation of Phase 2 data for its drug candidate ABCL635 at the IMS World Congress on Menopause 2026.

Past updates are part of the Pro plan.

Thematic Position

ABCL

Relationship Groups

Customers16
Partners17
Licensing4
Competitors12

Relationship details are part of the Pro plan.

Recent Discoveries

Recent discoveries are part of the Pro plan.

Ended Relationships

2 ended relationships · Ended relationships are part of the Pro plan.

Management Perspective on Regulatory & Geopolitical Developments

government rightsmarch-in rightsIP restriction
U.S. Bayh-Dole Act grants government march-in rights over federally funded IP
SEC 10-KFeb 24, 2026

The full regulatory passage is part of the Pro plan.

40 more · Regulatory and geopolitical insights are part of the Pro plan.